Business
Cardax Initiates Monkey Study to Compare Bioavailability of Patented Consumer Health Product Candidate CDX-085 to Microalgal Astaxanthin
Cardax Initiates Monkey Study to Compare Bioavailability of Patented Consumer Health Product Candidate CDX-085 to Microalgal Astaxanthin.
About this update from Cardax Inc
[{"type":"text","content":"\n \n Cardax, Inc. (“Cardax”) (OTCQB:CDXI) announced today that it initiated a \n single-dose pharmacokinetic study in non-human primates (monkeys) to \n compare the bioavailability (exposure) of CDX-085, the Company’s \n patented consumer health product candidate, to microalgal astaxanthin, \n the predominate astaxanthin consumer health form on the market.\n \n \n Results are anticipated in July and will inform the selection of a \n consumer health dose based on the relative exposure of nature-identical \n astaxanthin following oral administration of CDX-085. CDX-085 has \n demonstrated oral bioavailability in multiple animal studies in \n different species (mice, rats, dogs, monkeys) but has not been tested \n head-to-head against microalgal astaxanthin. Cardax is targeting product \n launch in 2016 following GRAS designation.\n \n \n Cardax believes that the current manufacturing capability of microalgal \n astaxanthin producers will not satisfy the growing demand for \n astaxanthin in human health applications and there is a need for \n synthetic production of bioavailable nature-identical astaxanthin \n products with high-purity, batch-to-batch consistency, and reliable \n large-volume supply at economical costs.\n \n \n “We look forward to the results of this study,” said Cardax CEO, David \n G. Watumull. “It furthers a critical component of our development \n strategy.”\n \n \n About Cardax\n \n \n Cardax is a development stage life sciences company that devotes \n substantially all of its efforts to developing consumer health and \n pharmaceutical products that it believes will provide many of the \n anti-inflammatory benefits of steroids or NSAIDS by targeting many of \n the same inflammatory pathways and mediators, but with exceptional \n safety profiles. Cardax is preparing proprietary nature-identical \n products and related derivatives by total synthesis to provide scalable, \n pure, and economical therapies for diseases where inflammation and \n oxidative stress are strongly implicated, including, but not limited to, \n osteoarthritis, rheumatoid arthritis, dyslipidemia, metabolic disease, \n diabetes, cardiovascular disease, hepatitis, cognitive decline, macular \n degeneration, and prostate disease. The initial primary focus of Cardax \n is its astaxanthin technologies. A...